Skip to main content

Table 3 CircN4BP2L2, CA125, and HE4 expression levels according to histology, menopause status, and FIGO stage; ROC AUC, sensitivity, specificity, and significant difference in EOC cohort vs benign ovarian cyst and normal cohorts

From: Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer

EOC cohort

Benign cohort

Normal cohort

 

Median (range)

Median (range)

ROC AUC (95% CI)

Sen

Spe

P-value

Median (range)

ROC AUC (95% CI)

Sen

Spe

P

CircN4BP2L2

17.5 (0.5–89.6)

62.9 (1.0–367.2)

0.82 (0.76–0.87)

80%

78%

<  0.01*

95.8 (10.9–410.7)

0.90 (0.87–0.94)

82%

90%

<  0.01*

 Pre-M

23.4 (2.0–89.6)

61.5 (1.0–344.3)

0.80 (0.73–0.88)

79%

77%

<  0.01*

87.4 (10.9–389.5)

0.90 (0.85–0.95)

79%

91%

<  0.01*

 Post-M

12.2 (0.5–77.2)

64.3 (1.9–367.2)

0.83 (0.76–0.90)

72%

87%

<  0.01*

109.4 (13.1–410.7)

0.90 (0.85–0.96)

77%

88%

<  0.01*

 Early stagea

12.6 (1–86.3)

 

0.81 (0.73–0.89)

69%

79%

<  0.01*

 

0.90 (0.85–0.95)

92%

71%

<  0.01*

 Late stagea

17.5 (0.5–89.6)

 

0.82 (0.76–0.88)

74%

84%

<  0.01*

 

0.91 (0.87–0.95)

79%

91%

<  0.01*

CA125

215.2 (16.3–5801)

54.1 (12.7–372.7)

0.69 (0.62–0.76)

73%

24%

<  0.01*

24.0 (4.1–68.8)

0.87 (0.83–0.92)

73%

72%

<  0.01*

 Pre-M

219.7 (16.3–5000)

54.8 (12.7–361.5)

0.69 (0.59–0.78)

74%

24%

<  0.01*

25.2 (6.7–68.8)

0.87 (0.81–0.93)

74%

68%

<  0.01*

 Post-M

202 (16.5–5801)

50.9 (16.3–372.7)

0.68 (0.58–0.79)

72%

23%

<  0.01*

22.8 (4.1–67.7)

0.87 (0.81–0.93)

72%

77%

<  0.01*

 Early stagea

28.6 (16.3–143.7)

 

0.33 (0.22–0.44)

42%

24%

<  0.01*

 

0.68 (0.58–0.78)

42%

72%

<  0.01*

 Late stagea

477.2 (21.8–5801)

 

0.83 (0.77–0.89)

86%

24%

<  0.01*

 

0.95 (0.92–0.98)

86%

72%

<  0.01*

HE4

106.3 (28.3–286.6)

46.1 (12.0–219.0)

0.73 (0.67–0.80)

67%

83%

<  0.01*

45.5 (11.2–235.0)

0.72 (0.65–0.78)

67%

85%

<  0.01*

 Pre-M

79.2 (31.7–218.0)

46.5 (14.0–219.0)

0.70 (0.61–0.79)

54%

80%

<  0.01*

45.9 (12.4–235.0)

0.66 (0.57–0.76)

54%

83%

<  0.01*

 Post-M

114.0 (28.3–286.6)

46.0 (12.0–207.0)

0.86 (0.79–0.93)

82%

87%

<  0.01*

43.6 (11.2–201.8)

0.83 (0.75–0.91)

82%

87%

<  0.01*

 Early stagea

70.4 (28.3–207.0)

 

0.64 (0.53–0.74)

42%

83%

0.01*

 

0.62 (0.52–0.73)

42%

85%

0.02*

 Late stagea

120.3 (31.7–286.6)

 

0.81 (0.75–0.88)

78%

83%

<  0.01*

 

0.79 (0.73–0.86)

78%

85%

<  0.01*

Combination

  

0.91 (0.88–0.95)

89%

87%

<  0.01*

 

0.99 (0.98–1.00)

91%

96%

<  0.01*

 Pre-M

  

0.97 (0.95–0.99)

85%

83%

<  0.01*

 

1.00

90%

95%

<  0.01*

 Post-M

  

0.97 (0.94–0.99)

92%

90%

<  0.01*

 

1.00

94%

98%

<  0.01*

  1. a According to International Federation of Gynecology and Obstetrics staging
  2. Abbreviations: EOC epithelial ovarian cancer, ROC receiver operating characteristic curve, AUC area under curve, 95% CI 95% confidence interval, Sen sensitivity, Spe specificity, Pre-M Pre-menopause, Post-M Post-Menopause
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us